“Medicine has become a pig trough here…we took a wrong turn when doctors stopped being doctors and became businessmen.” While this doctor was referring to
As the New Yorker article points out, more procedures in many cases offer marginal value as all procedures carry risk. Back surgery is a prime example. John Smith comes in for a bad back; doctor refers John to a colleagues boutique back surgery hospital; John leaves crippled with internal scarring and a new case of arachnoiditis. Specialized hospitals such as the one I mentioned in the example can be seen everywhere. Interestingly, the New Yorker mentions my hometown,
The Wall Street Journal recently discussed one--comparative effectiveness research. The Agency of Healthcare Quality Research (AHQR) is flush with $1.1B in stimulus funds and charged with comparing treatments, medicines, and making recommendations. While my most cynical colleagues might claim that this institute will eventually help justify "rationed care," but rationing already occurs every time a doctor opts one treatment over another. While it may seem by my post that I may think doctors are greedy, the truth couldn't be further from the truth--my dad is one. I've seen him work on the front lines as a family practitioner and pass up lucrative opportunities in favor of staying there. He eschews costly questionable treatments and thinks carefully how best he can improve the patient's quality of life. The solution comes from doctors sharing, collaborating, and setting up systems that are geared towards improving patient health. Bi-partisan consensus legislation can play a role in facilitating these relationships with funding for programs such as the AHQR, setting up peer review committees, and funding for research on different systems of care. Sadly, whether the government is writing a check or private insurers are doesn't address this fundamental problem… but that is best saved for another post.
We are certainly more medicated than we used to be, but I just don't know that the numbers back you up in the implication that boutique medicine is the main contributor to rising health care costs. It plays a role, to be sure, but I don't know that clamping down on ineffective treatments is going to necessarily give us the savings we need.
ReplyDeleteMoreover, while I completely am in support of comparative effectiveness research, and I agree that there is a potential role for the government to play there, I'm worried that the government will not be able to play an unbiased mediator of science if there is in fact a public option. Comparative effectiveness research would be best done without concerning costs - which treatment works best? Then, once we've found the more effective treatment, the second question of how to most efficiently (cheaply) use that treatment can be answered. So long as the person paying for comparative effectiveness science has an interest in finding the cheapest treatment rather than the
best overall, there's going to be shenanigans.